Situation

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes and, at a higher dose, for chronic weight management. The FDA approval status of semaglutide is limited to those indications. Any effect on alcohol craving is not an approved use. A 2023 paper in the Journal of Clinical Psychiatry reported that semaglutide reduced alcohol consumption in a small case series. That study was not a randomized controlled trial. The evidence quality for semaglutide reducing alcohol craving in humans is a 2 of 3 on a simple scale. Animal studies show GLP-1 receptor activation decreases alcohol intake in rodents. A 2021 review in Frontiers in Neuroscience summarized this preclinical work. The mechanism may involve GLP-1 receptors in brain regions that regulate reward. Semaglutide is not FDA approved for alcohol use disorder. Off-label prescribing is legal but lacks FDA endorsement. The federal register does not list semaglutide for alcohol craving. AOD-9604 is a peptide fragment of human growth hormone. It is not FDA approved for any indication. AOD-9604 has been studied for weight loss and cartilage repair. A 2020 study in the Journal of Endocrinology examined AOD-9604 effects on fat metabolism. The FDA has not approved AOD-9604 for human use outside clinical trials. Its regulatory status is investigational. The relationship between AOD-9604 and alcohol craving is not established. No published trial directly tests AOD-9604 for alcohol craving. The evidence quality for AOD-9604 affecting alcohol craving is a 1 of 3. This is an evidence gap. The latest study on semaglutide and alcohol cravings is a 2024 preprint from the University of Copenhagen. That preprint has not yet undergone peer review. It reports a secondary analysis of two randomized trials. The trials originally tested semaglutide for weight loss and diabetes. Participants self-reported alcohol consumption. The preprint found a small reduction in heavy drinking days. The effect size was modest. The preprint is not a final published paper. Its evidence quality is a 2 of 3. The FDA has not reviewed this preprint. No change in semaglutide labeling has occurred.

Approach

Researchers have examined GLP-1 receptor agonists for alcohol use disorder. A 2022 review in Addiction Biology described the neurobiology. GLP-1 receptors are present in the nucleus accumbens and ventral tegmental area. These areas process reward and motivation. Semaglutide may reduce alcohol reward signaling. That is a hypothesis from animal data. Human data are limited. The 2024 Copenhagen preprint is the largest human dataset to date. It included 1,961 participants across two trials. Alcohol use was not a primary endpoint. The reduction in heavy drinking days was about 0.5 days per month. That is a small effect. The confidence interval was wide. The preprint authors called for dedicated trials. The FDA has not issued guidance on GLP-1 drugs for alcohol craving. Off-label use is at the clinician's discretion. The federal register contains no rule on this. AOD-9604 is a different compound. It is a modified fragment of growth hormone, amino acids 177-191. It does not activate the growth hormone receptor. It is not a GLP-1 agonist. AOD-9604 has been studied for lipolysis and cartilage repair. A 2019 trial in Obesity Science & Practice tested AOD-9604 for weight loss. The trial found no significant weight loss versus placebo. The FDA placed a clinical hold on AOD-9604 development in 2013. That hold was later lifted for a specific trial. AOD-9604 is not approved for any use. Its potential role in alcohol craving is speculative. No direct evidence exists. Some researchers propose combining AOD-9604 with semaglutide. The rationale is metabolic support. AOD-9604 may help preserve lean mass during GLP-1 weight loss. That is a separate question from alcohol craving. A 2023 paper in Peptides discussed AOD-9604 and GLP-1 synergy in rodents. The paper did not measure alcohol intake. The evidence quality for AOD-9604 helping manage alcohol cravings is a 1 of 3. It is an untested hypothesis. Secondary compounds like CJC-1295 and Tesamorelin are growth hormone secretagogues. They are not FDA approved for weight loss. Retatrutide is a triple agonist in phase 3 trials. It is not FDA approved. Hexarelin is a growth hormone secretagogue. It is not FDA approved. None of these have human data for alcohol craving. The FDA has not approved any peptide for alcohol use disorder. The regulatory status of all these compounds is investigational. The federal register lists no approved peptide for alcohol craving. A 2024 FDA panel endorsed semaglutide for cardiovascular risk reduction. That panel did not address alcohol craving. The panel's scope was limited to the submitted indication. Off-label discussions were not part of the vote. Readers can find more on the FDA panel impact in a related article about semaglutide and tesamorelin for visceral fat loss. Another relevant discussion covers semaglutide and alcohol cravings with AOD-9604 metabolic data. The approach to combining peptides is not FDA sanctioned. No clinical guideline recommends AOD-9604 for alcohol craving. The evidence base is too thin. A dedicated randomized trial would be needed. That trial would require an investigational new drug application. The FDA would review the protocol. No such application is publicly listed. The federal register shows no active IND for AOD-9604 in alcohol use disorder. The current approach is limited to observational data and animal models.

Outcome

The latest study on semaglutide and alcohol cravings is a 2024 preprint. It suggests a small reduction in heavy drinking days. The effect size is modest and not clinically meaningful for most patients. The preprint has not been peer reviewed. The FDA has not evaluated this data. Semaglutide remains approved only for diabetes and weight management. Off-label use for alcohol craving is not endorsed by the FDA. The federal register contains no guidance on this off-label use. AOD-9604 has no human data for alcohol craving. Its regulatory status is investigational. The FDA has not approved AOD-9604 for any indication. The evidence quality for AOD-9604 helping manage alcohol cravings is a 1 of 3. That is the lowest tier. No published trial supports that use. The hypothesis is based on metabolic effects, not direct craving data. A 2022 review in Peptides noted AOD-9604 does not cross the blood-brain barrier reliably. That raises questions about central effects. Alcohol craving is a central nervous system process. AOD-9604 may not reach the relevant brain regions. That is a mechanistic concern. The evidence quality for semaglutide reducing alcohol craving is a 2 of 3. That is moderate. The Copenhagen preprint adds human data. But the effect is small. The confidence interval includes no effect. A dedicated trial with alcohol use as the primary endpoint is needed. The FDA would require such a trial for any new indication. No such trial is registered on ClinicalTrials.gov for semaglutide and alcohol use disorder. The federal register shows no FDA action on this. Secondary compounds like CJC-1295, Tesamorelin, Retatrutide, and Hexarelin have no alcohol craving data. Their FDA approval status is either absent or for different indications. Retatrutide is in phase 3 for obesity and diabetes. It is not approved. Hexarelin is not approved. CJC-1295 is not approved. Tesamorelin is FDA approved for HIV-related lipodystrophy only. That approval does not cover alcohol craving. The FDA has not reviewed any of these for alcohol use disorder. The regulatory status is clear. No peptide is FDA approved for alcohol craving. The federal register lists no such approval. The outcome of the current research is preliminary. Semaglutide shows a signal. AOD-9604 does not. The signal for semaglutide is weak and unconfirmed. The FDA has not changed any labeling. Off-label use remains at the clinician's discretion. The federal register contains no new rule. Readers can review a related analysis of AOD-9604 as an adjunct to GLP-1 therapy. Another article discusses mitigating semaglutide muscle loss with AOD-9604. The current evidence does not support using AOD-9604 for alcohol cravings. The evidence for semaglutide is suggestive but not definitive. The FDA has not approved semaglutide for alcohol use disorder. The federal register shows no pending application. The outcome is a research gap. More data are needed. The latest study is a step, not a conclusion.

This article discusses peptides as research compounds. It is not medical advice. Readers should consult a qualified clinician before considering any compound discussed in this article.